Indications & Uses
Zaltrap is indicated for:
Dosage Reference
Reference Information Only
Dosages shown are general references from official sources. Always consult your doctor or pharmacist for personalized dosing.
Adults:
Dosage 4 mg/kg as an intravenous infusion over 1 hour every 2 weeks. Do not administer as an intravenous (IV) push or bolus.
Side Effects
Most common adverse reactions (all grades, ≥20% incidence and at least 2% greater incidence for the Zaltrap/FOLFIRI regimen) were leukopenia, diarrhea, neutropenia, proteinuria, AST increased, stomatitis, fatigue, thrombocytopenia, ALT increased, hypertension, weight decreased, decreased appetite, epistaxis, abdominal pain, dysphonia, serum creatinine increased, and headache
Cautions & Contraindications
Warnings & Precautions
Adverse reactions, sometimes severe and life-threatening or fatal, have been seen in clinical trials with Zaltrap, including: Fistula Formation: Discontinue Zaltrap if fistula occurs. Hypertension: Monitor blood pressure and treat hypertension. Temporarily suspend Zaltrap if hypertension is not controlled. Discontinue Zaltrap if hypertensive crisis develops. Arterial Thromboembolic Events (ATE) (e.g., transient ischemic attacks, cerebrovascular accident, angina pectoris): Discontinue Zaltrap if ATE develops. Proteinuria: Monitor urine protein. Suspend Zaltrap when proteinuria ≥ 2 grams per 24 hours. Discontinue Zaltrap if nephrotic syndrome or thrombotic microangiopathy (TMA) develops. Neutropenia and Neutropenic Complications: Delay administration of Zaltrap/FOLFIRI until neutrophil count is ≥ 1.5 × 109/L. Diarrhea and Dehydration: Incidence of severe diarrhea and dehydration is increased. Monitor elderly patients more closely. Reversible Posterior Leukoencephalopathy Syndrome (RPLS): Discontinue Zaltrap.